S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
NASDAQ:AMED

Amedisys - AMED Stock Forecast, Price & News

$73.55
+1.66 (+2.31%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$72.36
$74.00
50-Day Range
$69.79
$100.33
52-Week Range
$69.36
$179.91
Volume
372,008 shs
Average Volume
436,569 shs
Market Capitalization
$2.39 billion
P/E Ratio
20.21
Dividend Yield
N/A
Price Target
$119.53

Amedisys MarketRank™ Forecast

Analyst Rating
Hold
2.36 Rating Score
Upside/​Downside
62.5% Upside
$119.53 Price Target
Short Interest
Healthy
5.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.42mentions of Amedisys in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$510,628 Sold Last Quarter
Proj. Earnings Growth
10.33%
From $4.26 to $4.70 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.05 out of 5 stars

Medical Sector

25th out of 1,004 stocks

Home Health Care Services Industry

3rd out of 9 stocks


AMED stock logo

About Amedisys (NASDAQ:AMED) Stock

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.

Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Stock News Headlines

The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Amedisys (NASDAQ:AMED) Stock Rating Upgraded by StockNews.com
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
What 10 Analyst Ratings Have To Say About Amedisys
Amedisys Q4 Profit Decreases, but beats estimates
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Company Calendar

Last Earnings
2/16/2023
Today
3/31/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
20,000
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$119.53
High Stock Price Forecast
$180.00
Low Stock Price Forecast
$85.00
Forecasted Upside/Downside
+62.5%
Consensus Rating
Hold
Rating Score (0-4)
2.36
Research Coverage
14 Analysts

Profitability

Net Income
$118.61 million
Pretax Margin
7.21%

Debt

Sales & Book Value

Annual Sales
$2.22 billion
Cash Flow
$7.30 per share
Book Value
$34.06 per share

Miscellaneous

Free Float
31,867,000
Market Cap
$2.39 billion
Optionable
Optionable
Beta
1.04

Social Links


Key Executives

  • Paul B. K. Kusserow
    Chairman & Chief Executive Officer
  • Scott G. GinnScott G. Ginn
    Chief Operating & Financial Officer & EVP
  • Michael P. NorthMichael P. North
    Chief Information Officer
  • Denise M. BohnertDenise M. Bohnert
    Chief Compliance Officer
  • Kendra Kimmons
    Vice President-Marketing & Communications













AMED Stock - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price forecast for 2023?

14 brokerages have issued 12 month price targets for Amedisys' stock. Their AMED share price forecasts range from $85.00 to $180.00. On average, they predict the company's share price to reach $119.53 in the next year. This suggests a possible upside of 62.5% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2023?

Amedisys' stock was trading at $83.54 on January 1st, 2023. Since then, AMED shares have decreased by 12.0% and is now trading at $73.55.
View the best growth stocks for 2023 here
.

Are investors shorting Amedisys?

Amedisys saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 1,800,000 shares, a drop of 13.9% from the February 28th total of 2,090,000 shares. Based on an average trading volume of 436,400 shares, the days-to-cover ratio is presently 4.1 days. Currently, 5.7% of the company's stock are sold short.
View Amedisys' Short Interest
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our AMED earnings forecast
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) announced its quarterly earnings data on Thursday, February, 16th. The health services provider reported $1.16 earnings per share for the quarter, topping analysts' consensus estimates of $1.03 by $0.13. The health services provider earned $562.10 million during the quarter, compared to analysts' expectations of $560.46 million. Amedisys had a net margin of 5.34% and a trailing twelve-month return on equity of 15.44%. The company's revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the company earned $1.18 EPS.

How will Amedisys' stock buyback program work?

Amedisys announced that its Board of Directors has authorized a stock buyback plan on Wednesday, August 4th 2021, which allows the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its stock is undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY23 earnings guidance on Wednesday, February, 15th. The company provided earnings per share guidance of $4.13-$4.36 for the period, compared to the consensus estimate of $4.88. The company issued revenue guidance of $2.244-$2.274 billion, compared to the consensus revenue estimate of $2.36 billion.

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (5.42%), Riverbridge Partners LLC (4.70%), Mackenzie Financial Corp (3.20%), Point72 Asset Management L.P. (1.70%), Credit Suisse AG (1.64%) and Millennium Management LLC (1.47%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Julie D Klapstein, Michael Paul North, Richard A Lechleiter, Scott G Ginn and Sharon Brunecz.
View institutional ownership trends
.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $73.55.

How much money does Amedisys make?

Amedisys (NASDAQ:AMED) has a market capitalization of $2.39 billion and generates $2.22 billion in revenue each year. The health services provider earns $118.61 million in net income (profit) each year or $3.64 on an earnings per share basis.

How many employees does Amedisys have?

The company employs 20,000 workers across the globe.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.

This page (NASDAQ:AMED) was last updated on 3/31/2023 by MarketBeat.com Staff